In recent years, the costs of new drug development have skyrocketed. The average cost of developing a new approved drug is now estimated to be $1.3 billion (DiMasi and Grabowski, 2007). At the same time, each year fewer new molecular entities (NMEs) are approved. DiMasi and Grabowski report that only 21.5 percent of the candidate drugs that enter phase I clinical testing actually make it to market. In 2007, just 17 novel drugs and 2 novel biologics were approved. In addition to the slowing rate of drug development and approval, recent years have seen a number of drugs withdrawn from the market for safety reasons. According to the Government Accountability Office (GAO), 10 drugs were withdrawn because of safety concerns between 2000 and March 2006 (GAO, 2006). Finding ways to select successful drug candidates earlier in development could save millions or even billions of dollars, reduce the costs of drugs on the market, and increase the number of new drugs with improved safety profiles that are available to patients.
Table of Contents |
skim chapter | |
---|---|---|
Front Matter | i-xvi | |
1 Introduction | 1-4 | |
2 Investigative Toxicology: The State of the Art | 5-12 | |
3 Screening Technologies I: Human Cell–Based Approaches | 13-27 | |
4 Screening Technologies II: Toxicogenomics | 28-49 | |
5 Screening Technologies III: Metabolomics | 50-58 | |
6 Screening Technologies IV: Pharmacogenetics | 59-64 | |
7 Qualifying Biomarkers | 65-73 | |
8 Pharmacovigilance | 74-92 | |
9 Integration | 93-105 | |
10 The Future of Safety Science | 106-114 | |
References | 115-116 | |
Appendix A: Workshop Agenda | 117-124 | |
Appendix B: Speaker Biographies | 125-134 |
The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:
For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.
Click here to obtain permission for Emerging Safety Science: Workshop Summary.
For information on how to request permission to translate our work and for any other rights related query please click here.
For questions about using the Copyright.com service, please contact:
Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
E-mail: info@copyright.com
Web: https://www.copyright.com
Loading stats for Emerging Safety Science: Workshop Summary...